Arcturus Therapeutics Holdings Inc. (ARCT) vs Orchestra BioMed Holdings, Inc. (OBIO)
A side-by-side comparison of Arcturus Therapeutics Holdings Inc. and Orchestra BioMed Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARCT
Arcturus Therapeutics Holdings Inc.
$13.40HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
OBIO
Orchestra BioMed Holdings, Inc.
$5.84HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — ARCT vs OBIO
growth of $100 · dividends reinvested · last 6yARCT -72.8% (-19.5%/yr)OBIO -47.1% (-10.1%/yr)OBIO compounded faster over this window
ARCT OBIO
ARCT vs OBIO: by the numbers
- •ARCT is the larger company ($381M vs $350M market cap).
- •Both run net losses; OBIO's is the smaller (-184.60% vs -391.90% net margin).
- •OBIO grew revenue faster over the past five years (148.45% vs 22.30% CAGR).
Metrics side by side
Valuation
| Metric | ARCT | OBIO |
|---|---|---|
| P/S ratio | 16.00 | 10.94 |
| P/B ratio | 2.22 | 18.10 |
Profitability
| Metric | ARCT | OBIO |
|---|---|---|
| Gross margin | 95.50% | 99.32% |
| Operating margin | -111.51% | -154.73% |
| Net margin | -391.90% | -184.60% |
| ROE | -54.29% | -200.64% |
| ROIC | -54.07% | -56.73% |
Growth (annualized)
| Metric | ARCT | OBIO |
|---|---|---|
| Revenue CAGR (5Y) | 22.30% | 148.45% |
| Total return CAGR (5Y) | -18.73% | -9.35% |
Frequently asked
- Which has grown faster, ARCT or OBIO?
- Over the past five years, OBIO grew revenue faster — ARCT at a 22.30% CAGR versus OBIO at 148.45%.
- How have ARCT and OBIO total returns compared?
- Over the past 5 years, ARCT delivered -18.73% and OBIO delivered -9.35% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arcturus Therapeutics ROEOrchestra BioMed ROEArcturus Therapeutics operating marginOrchestra BioMed operating marginArcturus Therapeutics revenue growthOrchestra BioMed revenue growthArcturus Therapeutics free cash flowOrchestra BioMed free cash flow
Arcturus Therapeutics & Orchestra BioMed appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.